$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
瑞格非尼 vs Lonsurf结直肠癌 的真实世界治疗模式
2025-10-19 11:44:20
Check Details
瑞格非尼治疗结直肠癌效果优于安慰剂
2025-10-19 11:44:20
Check Details
瑞格非尼治疗转移性结直肠癌
2025-10-19 11:44:20
Check Details
瑞格非尼治疗结直肠癌随机III期临床试验:日本和非日本人群分析
2025-10-19 11:44:20
Check Details
瑞格非尼用于经治晚期胃肠道间质瘤:III期GRID试验日本患者亚组分析
2025-10-19 11:44:20
Check Details
瑞格非尼治疗经治晚期胃肠道间质瘤患者的疗效和安全性:韩国多中心研究
2025-10-19 11:44:20
Check Details
瑞格非尼治疗转移性结直肠癌的效果
2025-10-19 11:44:20
Check Details
瑞格非尼治疗胃肠道间质瘤患II期临床试验
2025-10-19 11:44:20
Check Details
瑞格非尼治疗转移性结直肠癌的临床疗效
2025-10-19 11:44:20
Check Details
转移性结直肠癌治疗用药,瑞戈非尼
2025-10-19 11:44:20
Check Details
瑞格非尼针对结直肠癌的疗效
2025-10-19 11:44:20
Check Details
瑞格非尼(Regorafenib)治疗转移性结直肠癌
2025-10-19 11:44:20
Check Details
1
2
...
1595
1596
1597
1598
1599
1600
1601
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
2
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
3
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
4
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
5
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
6
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
7
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
8
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
9
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
10
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
11
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
12
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity